Drug Profile


Alternative Names: 115866; R115866; Rambazole

Latest Information Update: 24 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.
  • Developer Stiefel Laboratories
  • Class Azoles; Small molecules
  • Mechanism of Action Aromatase inhibitors; Cytochrome P 450 enzyme system inhibitors; Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acne; Psoriasis

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories acquired by GlaxoSmithKline
  • 07 Aug 2008 Barrier Therapeutics acquired by and merged into Stiefel Laboratories
  • 16 Feb 2007 No development reported - Phase-I/II for Skin disorders in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top